In the head-to-head REDEFINE 4 trial, CagriSema was found to be less effective than Eli Lilly's fast-growing GIP/GLP-1 agonist Zepbound (tirzepatide), which is currently setting the pace in the injectable weight-loss therapy category with sales rocketing to nearly $5 billion last year
Unlike some proteins that can refold after mild heat exposure, peptide drugs typically lose their functional structure permanently once denaturation passes a critical threshold
CrossRef Neuroprotective Activity of Eriodictyol Against Streptozotocin-Induced Diabetic Peripheral Neuropathy in Wistar Rats by Targeting Wnt/-Catenin Pathway Renu Malik, Balvinder Singh, Ajay Singh Kushwah, Manish Kumar NeuroMolecular Medicine.2025;[Epub] CrossRef Therapeutic potential of melatonin in management of diabetic mellitus and diabetic neuropathic pain: Underlying mechanisms, challenges and future perspectives Yaswanth Kuthati, Vaikar Navakanth Rao, Lokesh Kumar Mende, Chih-Shung Wong Journal of the Formosan Medical Association.2025;[Epub] CrossRef Mitochondrial DNA Stress Promotes the Ferroptosis of Endothelial Cells in Diabetic Peripheral Neuropathy by Upregulating ALOX15 Xuan Zhang, Yu Yue, Ling Zhang, Zhiqun Mou Critical Reviews in Eukaryotic Gene Expression.2025
Zhu et al., 2015) was found to be upregulated in 35S::SLIM1 at 44 DAS ( Figure 2D )
